H.W. Reesink

626 total citations
24 papers, 219 citations indexed

About

H.W. Reesink is a scholar working on Hepatology, Epidemiology and Infectious Diseases. According to data from OpenAlex, H.W. Reesink has authored 24 papers receiving a total of 219 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Hepatology, 10 papers in Epidemiology and 5 papers in Infectious Diseases. Recurrent topics in H.W. Reesink's work include Hepatitis C virus research (19 papers), Liver Disease Diagnosis and Treatment (9 papers) and Hepatitis B Virus Studies (6 papers). H.W. Reesink is often cited by papers focused on Hepatitis C virus research (19 papers), Liver Disease Diagnosis and Treatment (9 papers) and Hepatitis B Virus Studies (6 papers). H.W. Reesink collaborates with scholars based in Netherlands, United States and Germany. H.W. Reesink's co-authors include Christine J. Weegink, Robert J. de Knegt, Hans L. Zaaijer, Joep de Bruijne, Richard Molenkamp, Susan Purdy, Harry L.A. Janssen, Jean‐François Bergmann, A.A. van Vliet and James R. Appleman and has published in prestigious journals such as Journal of Hepatology, Alimentary Pharmacology & Therapeutics and Journal of Medical Virology.

In The Last Decade

H.W. Reesink

24 papers receiving 210 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
H.W. Reesink Netherlands	9	178	175	49	37	19	24	219
Jieting Huang China	12	218 1.2×	213 1.2×	59 1.2×	45 1.2×	42 2.2×	30	333
Kristina Cardell Sweden	9	287 1.6×	223 1.3×	45 0.9×	79 2.1×	16 0.8×	12	341
Hanna Berak Poland	9	127 0.7×	149 0.9×	37 0.8×	30 0.8×	26 1.4×	41	191
Y. Lazizi France	10	186 1.0×	199 1.1×	45 0.9×	30 0.8×	16 0.8×	13	262
Zu‐Jiang Yu China	9	111 0.6×	104 0.6×	30 0.6×	21 0.6×	27 1.4×	15	184
Jianling Li United States	5	129 0.7×	124 0.7×	94 1.9×	28 0.8×	12 0.6×	7	243
Sophie B. Willemse Netherlands	12	210 1.2×	205 1.2×	29 0.6×	19 0.5×	45 2.4×	21	283
Junfeng Lu China	10	300 1.7×	275 1.6×	30 0.6×	45 1.2×	27 1.4×	32	359
Lisa Sandmann Germany	9	211 1.2×	191 1.1×	26 0.5×	16 0.4×	21 1.1×	33	283
J Cianciara Poland	10	289 1.6×	289 1.7×	50 1.0×	18 0.5×	18 0.9×	35	328

Countries citing papers authored by H.W. Reesink

Since Specialization

Citations

This map shows the geographic impact of H.W. Reesink's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by H.W. Reesink with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites H.W. Reesink more than expected).

Fields of papers citing papers by H.W. Reesink

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by H.W. Reesink. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by H.W. Reesink. The network helps show where H.W. Reesink may publish in the future.

Co-authorship network of co-authors of H.W. Reesink

This figure shows the co-authorship network connecting the top 25 collaborators of H.W. Reesink. A scholar is included among the top collaborators of H.W. Reesink based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with H.W. Reesink. H.W. Reesink is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Stelma, F., Élise Roy, Patrice André, et al.. (2018). First clinical evaluation in chronic hepatitis B patients of the synthetic farnesoid X receptor agonist EYP001. Journal of Hepatology. 68. S488–S489. 10 indexed citations

Willemse, Sophie B., Devin Razavi‐Shearer, Freke Zuure, et al.. (2015). The estimated future disease burden of hepatitis C virus in the Netherlands with different treatment paradigms.. PubMed. 73(9). 417–31. 16 indexed citations

Stelma, F., Sophie B. Willemse, Marc van der Valk, et al.. (2015). LO7 : A single subcutaneous dose of 2mg/kg or 4mg/kg of RG-101, a GalNAc-conjugated oligonucleotide with antagonist activity against MIR-122, results in significant viral load reductions in chronic hepatitis C patients. Journal of Hepatology. 62. S261–S261. 8 indexed citations

Zeuzem, Stefan, Marta Colombo, Robert Flisiak, et al.. (2014). P1119 EARLY VIRAL KINETICS DO NOT PREDICT TREATMENT OUTCOME WITH SOFOSBUVIR + RIBAVIRIN FOR 12 OR 24 WEEKS IN HCV GENOTYPE 2/3 PATIENTS IN THE VALENCE TRIAL. Journal of Hepatology. 60(1). S452–S452. 5 indexed citations

Sarrazin, C., H.W. Reesink, Stefan Zeuzem, et al.. (2013). 898 TREATMENT WITH TELAPREVIR/PEG-IFN/RBV AFTER 14-DAY TELAPREVIR EXPOSURE IN PHASE I STUDIES: RESULTS FROM THE PHASE IIIB C219 ROLLOVER STUDY. Journal of Hepatology. 58. S369–S370. 3 indexed citations

Boucher, Charles A., J.T. Brouwer, David M. Burger, et al.. (2013). Treatment of hepatitis C monoinfection in adults--Dutch national guidelines.. PubMed. 71(7). 377–85. 8 indexed citations

Picchio, Gastón, C. Sarrazin, H.W. Reesink, et al.. (2012). T-24 Retreatment with telaprevir/Peg-IFN/RBV after a short exposure to telaprevir in Phase I studies: interim results from a Phase IIIb rollover trial (C219). Digestive and Liver Disease. 44. S22–S22. 6 indexed citations

Bergmann, Jean‐François, Joep de Bruijne, Robert J. de Knegt, et al.. (2011). Randomised clinical trial: anti-viral activity of ANA773, an oral inducer of endogenous interferons acting via TLR7, in chronic HCV. Alimentary Pharmacology & Therapeutics. 34(4). 443–453. 43 indexed citations

Thomas, Xiomara V., Joep de Bruijne, Tara L. Kieffer, et al.. (2011). 1242 LONG-TERM FOLLOW-UP OF CHRONIC HEPATITIS C INFECTED PATIENTS TREATED WITH TELAPREVIR: EVALUATION OF PERSISTENCE OF RESISTANT VARIANTS BY ULTRA-DEEP SEQUENCING. Journal of Hepatology. 54. S490–S491. 7 indexed citations

10.

Lenz, Oliver, Joep de Bruijne, Leen Vijgen, et al.. (2011). 1221 TREATMENT OUTCOME AND RESISTANCE ANALYSIS IN HCV GENOTYPE 1 PATIENTS PREVIOUSLY EXPOSED TO TMC435 MONOTHERAPY AND RE-TREATED WITH TMC435 IN COMBINATION WITH PEGIFNα-2A/RIBAVIRIN. Journal of Hepatology. 54. S482–S483. 7 indexed citations

11.

Bruijne, Joep de, Jean‐François Bergmann, Christine J. Weegink, et al.. (2010). 746 NARLAPREVIR AND PEGINTERFERON ALFA-2B FOR 2 WEEKS IN CHRONIC HEPATITIS C GENOTYPE 1 PATIENTS, FOLLOWED BY PEGINTERFERON ALFA-2B AND RIBAVIRIN FOR 24/48 WEEKS: FINAL RESULTS. Journal of Hepatology. 52. S290–S291. 2 indexed citations

12.

Takkenberg, R. Bart, Hans L. Zaaijer, Richard Molenkamp, et al.. (2009). Validation of a sensitive and specific real‐time PCR for detection and quantitation of hepatitis B virus covalently closed circular DNA in plasma of chronic hepatitis B patients. Journal of Medical Virology. 81(6). 988–995. 25 indexed citations

13.

Zaaijer, Hans L., Valeska Terpstra, M.G.W. Dijkgraaf, et al.. (2009). 15 BASELINE HBsAg LEVEL PREDICT HBsAg LOSS IN CHRONIC HEPATITIS B PATIENTS TREATED WITH A COMBINATION OF PEGINTERFERON ALFA-2A AND ADEFOVIR: AN INTERIM ANALYSIS. Journal of Hepatology. 50. S8–S8. 7 indexed citations

14.

Manns, M.P., H.W. Reesink, Christophe Moreno, et al.. (2009). 11 OPERA-1 TRIAL: INTERIM ANALYSIS OF SAFETY AND ANTIVIRAL ACTIVITY OF TMC435 IN TREATMENT-NAIVE GENOTYPE 1 HCV PATIENTS. Journal of Hepatology. 50. S7–S7. 20 indexed citations

15.

Marcellin, Patrick, H.W. Reesink, Thomas Berg, et al.. (2009). 1058 ANTIVIRAL ACTIVITY AND SAFETY OF TMC435 COMBINED WITH PEGINTERFERON ALPHA-2A AND RIBAVIRIN IN PATIENTS WITH GENOTYPE 1 HEPATITIS C INFECTION WHO FAILED PREVIOUS IFN-BASED THERAPY. Journal of Hepatology. 50. S385–S385. 12 indexed citations

16.

Neumann, Avidan U., et al.. (2007). [625] NOVEL MODE OF VIRAL DECLINE DURING TELAPREVIR (VX-950) AND PEG-IFN COMBINATION TREATMENT PREDICTED BY A NEW COMBINED INTRACELLULAR AND CELLULAR HEPATITIS C VIRAL DYNAMICS MODEL. Journal of Hepatology. 46. S236–S236. 1 indexed citations

17.

Gelderblom, Huub C., Stefan Zeuzem, Nicole Forestier, et al.. (2007). [592] NEOPTERIN AND ALT AS MARKERS OF INFLAMMATION IN CHRONIC HEPATITIS C PATIENTS DURING ADMINISTRATION OF THE HCV NS3-4A PROTEASE INHIBITOR TELAPREVIR (VX-950) IN COMBINATION WITH PEGINTERFERON ALFA 2a. Journal of Hepatology. 46. S224–S225. 2 indexed citations

18.

Friedrich‐Rust, Mireen, Nicole Forestier, C. Sarrazin, et al.. (2007). [539] ULTRASOUND EVALUATION OF PERIHEPATIC LYMPH NODES DURING ANTIVIRAL THERAPY WITH THE PROTEASE INHIBITOR TELAPREVIR (VX-950) IN PATIENTS WITH CHRONIC HEPATITIS C INFECTION. Journal of Hepatology. 46. S205–S205. 1 indexed citations

19.

Aach, Richard D., William L. Bayer, Robert J. Gerety, et al.. (1983). Based on Your Analysis of the Benefits and Costs of RoutineDonor Screening for ALT-GPT to Reduce the Incidence ofPost-Transfusion Non-A, Non-B Hepatitis in Your BloodServices Region, what Action Would You Recommend onThis Matter?. Vox Sanguinis. 44(1). 48–64. 6 indexed citations

20.

Aach, Richard D., Harrison Alter, L. F. Barker, et al.. (1981). Should Donors with a History of Jaundice Still be Rejected?. Vox Sanguinis. 41(2). 110–127. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact